Anteris Technologies Global Corp. (NASDAQ:AVR) Stock Now Rated “Hold” by Sell-Side Analysts

Anteris Technologies Global Corp. (NASDAQ:AVR) has been given an average recommendation of “Hold” by the five ratings firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $14.00.

A number of research firms have recently weighed in on AVR. Barclays upgraded shares of Anteris Technologies Global to a “hold” rating in a report on Wednesday, October 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anteris Technologies Global in a research note on Wednesday, August 26th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $15.00 target price on shares of Anteris Technologies Global in a research report on Wednesday, October 14th.

Anteris Technologies Global Price Performance

Shares of NASDAQ AVR opened at $6.05 on Monday. Anteris Technologies Global has a 1-year low of $3.30 and a 1-year high of $11.06. The business has a fifty day moving average price of $8.18 and a 200 day moving average price of $8.07. The stock has a market capitalization of $589.63 million, a P/E ratio of -3.10 and a beta of 1.87.

Anteris Technologies Global (NASDAQ:AVR) last posted its earnings results on Tuesday, August 11th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.09). The company had revenue of $1.01 million during the quarter, compared to analysts’ expectations of $1.50 million. Anteris Technologies Global had a negative net margin of 4,619.27% and a negative return on equity of 77.69%. During the same quarter last year, the firm earned ($0.58) EPS. As a group, equities research analysts anticipate that Anteris Technologies Global will post -1.21 earnings per share for the current fiscal year.

Insider Buying and Selling at Anteris Technologies Global

In related news, major shareholder L1 Capital Pty Ltd acquired 272,695 shares of the company’s stock in a transaction dated Tuesday, October 6th. The shares were purchased at an average cost of $7.18 per share, with a total value of $1,957,950.10. Following the completion of the acquisition, the insider directly owned 6,358,271 shares of the company’s stock, valued at $45,652,385.78. This represents a 4.48% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last 90 days, insiders have acquired 1,554,730 shares of company stock worth $11,694,513 and have sold 3,008,459 shares worth $25,243,576. 4.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Anteris Technologies Global

Institutional investors and hedge funds have recently modified their holdings of the company. Cetera Investment Advisers lifted its stake in Anteris Technologies Global by 64.7% during the 1st quarter. Cetera Investment Advisers now owns 16,550 shares of the company’s stock valued at $92,000 after acquiring an additional 6,500 shares during the period. Bank of America Corp DE increased its stake in shares of Anteris Technologies Global by 12.6% in the first quarter. Bank of America Corp DE now owns 68,755 shares of the company’s stock worth $382,000 after acquiring an additional 7,688 shares during the period. Legal & General Group Plc acquired a new stake in shares of Anteris Technologies Global in the second quarter worth $78,000. Bartlett & CO. Wealth Management LLC increased its stake in shares of Anteris Technologies Global by 174.5% in the first quarter. Bartlett & CO. Wealth Management LLC now owns 12,900 shares of the company’s stock worth $79,000 after acquiring an additional 8,200 shares during the period. Finally, Abel Hall LLC acquired a new stake in shares of Anteris Technologies Global in the first quarter worth $63,000.

Anteris Technologies Global Company Profile

Anteris Technologies Global is a clinical-stage structural heart company developing technologies intended to treat aortic valve disease. The company’s lead product is the DurAVR transcatheter heart valve, which is designed to replicate the performance characteristics of a healthy human aortic valve and restore more natural blood flow.

Anteris uses its proprietary ADAPT tissue-engineering technology to create heart-valve materials designed for durability and biocompatibility. The company is focused primarily on transcatheter aortic valve replacement and related structural-heart applications, with its products progressing through clinical development and regulatory evaluation rather than broad commercial distribution.

The company has Australian origins and maintains operations and clinical-development activities in both Australia and the United States.